title: Targeting platelets containing electro-encapsulated iloprost to balloon injured aorta in rats.
abstract: Drugs can be electro-encapsulated within platelets and targeted to damaged blood vessels by exploiting the platelet's natural haemostatic properties to adhere to collagen and other vessel wall constituents revealed by injury. A rat aorta balloon angioplasty model has been used to study the effect on platelet deposition of giving iloprost loaded platelets i.v. during the balloon injury. After labelling the circulating platelets with 111-Indium before balloon injury, time course studies showed maximum platelet deposition on the injured aorta occurred at about 1 h post-injury and the deposition remained stable over the next 2-3 h. When iloprost-loaded platelets were given i.v. during injury and the circulating platelet pool labelled with 111-Indium 30 min later, platelet deposition, measured at 2 h postinjury, was substantially and significantly reduced compared with control platelet treatment. Some anti-proliferative effects of iloprost-loaded platelets given i.v. during injury have also been observed. Whereas the incorporation of [3H]-thymidine into aorta intima-media DNA at 3 days post injury was 62-fold higher in balloon injured rats than in control sham operated rats, thymidine incorporation into intima/media of rats which had received iloprost loaded platelets during injury was reduced as compared with rats subjected only to the injury procedure. The reduction was only of near significance, however, but at 14 days after injury the total DNA content of the aorta intima/media of rats given iloprost loaded platelets during injury was significantly reduced. Although iloprost loaded platelets can clearly inhibit excessive platelet deposition, other encapsulated agents may have greater anti-proliferative effects.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Biochemistry & Chemistry, Royal Free Hospital School of Medicine, Hampstead, London, UK.
authors.forename: N
authors.initials: N
authors.lastname: Crawford
authors.forename: A
authors.initials: A
authors.lastname: Chajara
authors.forename: G
authors.initials: G
authors.lastname: Pfliegler
authors.forename: B
authors.initials: B
authors.lastname: el Gamal
authors.forename: L
authors.initials: L
authors.lastname: Brewer
authors.forename: L
authors.initials: L
authors.lastname: Capron
mesh_terms: D000800:Angioplasty, Balloon / Q000009:adverse effects*; D000818:Animals; D001011:Aorta / Q000293:injuries* / Q000473:pathology; D001792:Blood Platelets; D003094:Collagen / Q000378:metabolism; D004337:Drug Carriers; D004339:Drug Compounding / Q000379:methods; D004730:Endothelium, Vascular / Q000293:injuries* / Q000378:metabolism; D016285:Iloprost / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D007275:Injections, Intravenous; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D004337:Drug Carriers; D007205:Indium Radioisotopes; D003094:Collagen; D016285:Iloprost